Ocular medication delivery is the main issue facing pharmacologists and formulation scientists today. The most practical and patient-friendly drug delivery method, particularly again for management of diseases of the anterior segment, is topical eye drops. Various precorneal, dynamic, and static ocular barriers prevent medication delivery to the specific ocular tissues. Additionally, target tissues do not retain therapeutic medication levels for a a lengthy time frame.
The development of innovative, secure, and patient-compliant medication formulations and therapeutic agents instruments, which can overcome these obstacles and sustain medication levels in tissues, has increased over the past two decades in the field of ocular drug delivery research. The medicine was directly injected into the posterior part of the eye via intravitreal injection, a procedure that is invasive and has significant side effects. Therefore, a less intrusive medication delivery method should target the posterior part of the eye. The medication distribution concept was developed and simulated using commercial finite element software employing a micro-channels module inserted between top and bottom covers with a drug reservoir (COMSOL).
We outline the general strategies for the current implant device-based treatments utilized to treat retinal disorders in this study. We provide our opinions on potential approaches and difficulties for creating more potent device-based treatments for retinal disorders.
